Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial

Authors: Noel W. Clarke, Paweł Wiechno, B. Yа. Alekseev, Núria Sala, Robert H. Jones, Ivo Kocák, Vincenzo Emanuele Chiurì, Jacek Jassem, Aude Fléchon, Charles H. Redfern, Carsten Goessl, Joseph E. Burgents, Robert Kozarski, Darren Hodgson, Maria Learoyd, Fred Saad - The Lancet 2018 cited by 409